Poster Presentation Details:
Title: Prior Specialist Consultations and Treatments in A Refractory Chronic Cough Population Enrolled in A Phase 2b Study of The P2X3 Antagonist BLU-5937
Session: Signs and Symptoms of Chest Disease
CHEST has announced that the abstract will be made available today on the CHEST® journal website here. Following the conference, the presentation materials will be available in the “Scientific Publications” section of
Chronic cough is a cough lasting longer than eight weeks. When the cause of chronic cough cannot be identified or the cough persists despite treatment of all identified associated causes, the condition is referred to as RCC. It is estimated that there are approximately 9 million patients in
The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations, the
Chief Financial Officer